Provided By GlobeNewswire
Last update: Nov 10, 2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”).
Read more at globenewswire.comNASDAQ:PROF (11/19/2025, 2:57:58 PM)
5.96
-0.27 (-4.33%)
Find more stocks in the Stock Screener


